Status:
RECRUITING
Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort
Lead Sponsor:
Thomas Scherer
Collaborating Sponsors:
Medical University of Graz
University of Graz
Conditions:
Obesity
Aging
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this prospective observational study is to identify and validate blood based aging biomarkers in relation to cardiometabolic phenotypes of young and old, female and male subjects with or w...
Detailed Description
The ongoing increase in human life expectancy is steadily reshaping the demographic landscape, leading to a higher proportion of older adults, many of whom suffer from multiple health conditions. Thes...
Eligibility Criteria
Inclusion
- Group 1 - Lean, young adults (n = 150)
- Age 18 - 35 years
- Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months)
- Group 2 - Overweight, young adults (n = 150)
- Age 18 - 35 years
- BMI ≥ 28kg/m2 (≥ 12 months)
- Group 3 - Lean, older adults (n = 150)
- Age ≥ 60 years
- BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years)
- Group 4 - Overweight, older adults (n = 150)
- Age ≥ 60 years
- BMI ≥ 28 kg/m2 (≥ 3 years)
- Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II).
- Subgroup B (n=75): without pre-existent cardiovascular disease
- Group 5 - Nonagenerians Age ≥ 90 (n = 50)
- Age ≥ 90 years
- BMI ≥ 18.5 kg/m2 (≥ 3 years)
Exclusion
- Group 1 - Lean, young adults (n = 150)
- Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
- Special diets (i.e. ketogenic diet and time-restricted eating)
- Clinically significant metabolic or endocrine disorders
- Claustrophobia
- drug abuse, alcohol \> 15 drinks/week
- Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
- Metal implants that prohibit 3T MRI
- Pregnancy or breastfeeding
- Group 2 - Overweight, young adults (n = 150)
- Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
- Special diets (i.e. ketogenic diet and time-restricted eating)
- Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion)
- Clinically significant metabolic or endocrine disorders
- Claustrophobia
- drug abuse, alcohol \> 15 drinks/week
- Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
- Metal implants that prohibit 3T MRI
- Pregnancy or breastfeeding
- Group 3 - Lean, older adults (n = 150)
- Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
- Special diets (i.e. ketogenic diet and time-restricted eating)
- Diabetes, overt hypo/hyperthyroidism
- Claustrophobia
- drug abuse, alcohol \> 15 drinks/week
- Metal implants that prohibit 3T MRI
- Known severe cardiovascular diseases (i.e. PAD IIa or higher, advanced heart failure = left ventricular ejection fraction (LVEF) \< 35% or NYHA Class III-IV)
- No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
- Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
- Group 4 - Overweight, older adults (n = 150)
- Special diets (i.e. ketogenic diet and time-restricted eating)
- Diabetes, overt hypo/hyperthyroidism
- Active anti-obesity treatment (e.g. GLP-1 analogues, polyagonists, naltrexone and bupropion)
- Claustrophobia
- drug abuse, alcohol \> 15 drinks/week
- Metal implants that prohibit 3T MRI
- No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
- Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
- Group 5 - "healthy" Nonagenerians Age ≥ 90 (n = 50)
- Claustrophobia
- Clinically significant cognitive impairment compromising study adherence
- Metal implants that prohibit 3T MRI
- Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
Key Trial Info
Start Date :
May 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2036
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT06511297
Start Date
May 5 2025
End Date
January 1 2036
Last Update
August 26 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz
Graz, Styria, Austria
2
Medical University of Vienna
Vienna, Vienna, Austria